Allia Shuaib1*, Abdelrahman H Al Harazi2
1Department of Obstetrics and Gynecology, Faculty of Medicine and Health Sciences, Sana'a University, 2Department of Obstetrics and Gynecology, Faculty of Medicine, Thamar University
Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder that affects about 6-8% of women during the reproductive age 1 .The pathological mechanisms of PCOS are not fully understood but the data indicate that insulin resistance (IR) likely plays a central role in the pathophysiology of PCOS which results in secondary hyperinsulinemia 2. The increased insulin levels leads to excess androgen synthesis by the ovarian theca cells and is made worse by obesity 2. It is reported that IR and thus hyperinsulinemia affects approximately 60-70 % of women with PCOS and 40 – 60% of PCOS women are obese 3. The initial studies have shown that the
agent which ameliorates insulin resistance and reduces circulating insulin levels such as Metformin may improve the condition 4. Several studies reported the beneficial effects of Metformin on the clinical and biochemical parameters of PCSO women 5,6. However, since not all women with PCSO have insulin resistance or obesity, it is unclear if PCOS women with normal body weight and normoinsulinemia also benefit from Metformin treatment. Aim of the study: The aim of this study was to explore whether or not metformin therapy can improve the clinical and / or biochemical parameters of PCOS in this sub group of women.